deltatrials
Terminated PHASE1 INTERVENTIONAL 7-arm NCT01243762

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer

Sponsor: Merck Sharp & Dohme LLC

Conditions Neoplasms Malignant
Interventions MK-0752 MK-2206 dalotuzumab ridaforolimus
Updated 12 times since 2017 Last updated: Jul 18, 2018 Started: Nov 22, 2010 Primary completion: Dec 4, 2012 Completion: Mar 25, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

A PHASE1 clinical study on Neoplasms Malignant, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 12 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshotTerminated~Nov 2017 – ~May 2018 · 6 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotTerminated~Sep 2018 – ~Nov 2020 · 26 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshotTerminated~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE1

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

▶ Show 7 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

  2. Sep 2018 — Nov 2020 [monthly]

    Terminated PHASE1

  3. Jun 2018 — Sep 2018 [monthly]

    Terminated PHASE1

  4. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1

  5. Nov 2017 — May 2018 [monthly]

    Terminated PHASE1

  6. Feb 2017 — Nov 2017 [monthly]

    Terminated PHASE1

  7. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.